ClearView Diagnostics

About ClearView Diagnostics

ClearView Diagnostics has developed deep-learning/AI software to target and identify breast cancer – providing radiologists a quick and inexpensive way to indicate whether or not a woman has breast cancer. Leveraging funding from seed capital, ClearView has been awarded two rounds of National Institutes of Health (NIH) grants to undergo extensive studies in Mexico. In January 2017 the FDA issued a 510(k) for the ClearView cCAD product and the team is moving forward to test in the United States with University Radiology Group, one of the largest, most subspecialized, Board Certified radiology practices in the U.S.